ClinicalTrials.gg
CompletedNCT00316225Updated Jul 9, 2010Results posted

Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

A Phase 2 interventional study of pemetrexed in Non-small Cell Lung Cancer, Mesothelioma and Lung Neoplasms, sponsored by Eli Lilly and Company. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-07-09.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
157th of 224
31 · median 65
Started
2006
with 24 others
Phase 2
128 of 228
12 open now
Registered
33rd of 228
by date
Lead sponsor
40 of 228
Eli Lilly and Company

Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 157th largest by enrollment of the 224 interventional ones that give a count, is one of 25 that started in 2006, is one of 128 in phase 2, and was the 33rd registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.

03

Conditions studied

  • Non-small Cell Lung Cancer
  • Mesothelioma
  • Lung Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of locally advanced or (Stage III or IV at entry) non-small cell lung cancer (NSCLC) or mesothelioma
  • Presence of third-space fluid (fluid around the lungs or abdomen).
  • Performance Status of 0 or 1.
  • Prior anticancer treatment (except radiation) must be completed at least 3 weeks prior to study enrollment, and the patient must have recovered from the sharp toxic effects the anticancer treatment.
  • Estimated of at least 8 weeks.

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within the last 30 days with a drug that was not a marketed product.
  • Active infection that, in the opinion of the investigator, would not allow the patient to tolerate therapy.
  • Pregnancy.
  • Breast-feeding.
  • Significant weight loss (that is, greater than or equal to 10% of body weight) over the 6 weeks before study entry.
  • .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    Pemetrexed 500 mg/m\^2 intravenous (IV) every 21 days for 6 cycles

    Drug: pemetrexed

Interventions

  • 500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles

    Also known as: LY231514, Alimta

06

What researchers measure

Primary outcomes

  1. Overview of Adverse Events

    Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: baseline, up to 18 weeks

Secondary outcomes

  1. Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities

    Number of participants with laboratory and non-laboratory toxicities possibly related to study drug, which were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. Grades range from 0 (none) to 5 (death). Grade 3 is severe and Grade 4 is life-threatening. NOS = Not otherwise specified.

    Time frame: baseline, up to 18 weeks

  2. Pemetrexed Population Pharmacokinetics (PK): Clearance

    Clearance (CL) can be defined as the volume of plasma which is completely cleared of drug (pemetrexed) per unit time. Total body clearance is calculated after intravenous administration of the drug (pemetrexed) and is measured by taking plasma samples at various timepoints and measuring the amount of pemetrexed in the plasma.

    Time frame: Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion

  3. Pemetrexed Population Pharmacokinetics: Volume of Distribution

    Volume of distribution is the theoretical size of the compartment necessary to account for total drug amount in the body if it were present throughout the body in the same concentration found in plasma. Volume of distribution is defined as distribution of pemetrexed in the body and is determined by volume of distribution = dose/drug concentration. By knowing dose and measuring concentration of pemetrexed in plasma, volume was calculated. Central volume (V1) was determined by dose/peak serum level of pemetrexed. Peripheral volume (V2) is sum of all tissue spaces outside the central compartment.

    Time frame: Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion

  4. Discontinuations Due to Adverse Events

    Adverse events were coded using the Medical Dictionary for Regulatory Activities, Version 11.0.

    Time frame: baseline, up to 18 weeks

Other outcomes

  1. Overall Tumor Response

    Overall tumor response was determined using Response Evaluation Criteria In Solid Tumors (RECIST), which defines when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. CR (complete response) = disappearance of all target lesions. PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions. PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions. SD (stable disease) = small changes that do not meet above criteria.

    Time frame: baseline, up to 18 weeks

07

Results

Posted Jul 9, 2010

Participant flow

Participant flow — Overall Study
MilestonePemetrexed
Started31
Completed6
Not completed25
Withdrew: Adverse event2
Withdrew: Physician decision3
Withdrew: Progressive disease15
Withdrew: Withdrawal by subject3
Withdrew: Death2

Outcome measures

SecondaryNumber of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities

Number of participants with laboratory and non-laboratory toxicities possibly related to study drug, which were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. Grades range from 0 (none) to 5 (death). Grade 3 is severe and Grade 4 is life-threatening. NOS = Not otherwise specified.

Time frame:
baseline, up to 18 weeks
Reported as:
Number · participants
Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities
participantsPemetrexed
Leukocytopenia1
Neutropenia/Granulocytopenia1
Platelets1
Ascites (Non-Malignant)1
Febrile Neutropenia1
Pain Pulmonary/Upper Respiratory-Chest/Thorax NOS1
Pleural Effusion (Non-Malignant)1
SecondaryPemetrexed Population Pharmacokinetics (PK): Clearance

Clearance (CL) can be defined as the volume of plasma which is completely cleared of drug (pemetrexed) per unit time. Total body clearance is calculated after intravenous administration of the drug (pemetrexed) and is measured by taking plasma samples at various timepoints and measuring the amount of pemetrexed in the plasma.

Time frame:
Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion
Reported as:
Mean · milliliter per minute (mL/min)
Pemetrexed Population Pharmacokinetics (PK): Clearance
milliliter per minute (mL/min)Pemetrexed
Pemetrexed Population Pharmacokinetics (PK): Clearance85.6 ± 21.4
SecondaryPemetrexed Population Pharmacokinetics: Volume of Distribution

Volume of distribution is the theoretical size of the compartment necessary to account for total drug amount in the body if it were present throughout the body in the same concentration found in plasma. Volume of distribution is defined as distribution of pemetrexed in the body and is determined by volume of distribution = dose/drug concentration. By knowing dose and measuring concentration of pemetrexed in plasma, volume was calculated. Central volume (V1) was determined by dose/peak serum level of pemetrexed. Peripheral volume (V2) is sum of all tissue spaces outside the central compartment.

Time frame:
Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion
Reported as:
Mean · Liters (L)
Pemetrexed Population Pharmacokinetics: Volume of Distribution
Liters (L)Pemetrexed
Central Volume of Distribution6.61 ± 1.32
Peripheral Volume of Distribution (V2)8.91 ± 1.68
Peripheral Volume of Distribution (V3)1.26 ± 0
Other pre-specifiedOverall Tumor Response

Overall tumor response was determined using Response Evaluation Criteria In Solid Tumors (RECIST), which defines when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. CR (complete response) = disappearance of all target lesions. PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions. PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions. SD (stable disease) = small changes that do not meet above criteria.

Time frame:
baseline, up to 18 weeks
Reported as:
Number · participants
Overall Tumor Response
participantsPemetrexed
Complete Response0
Partial Response2
Stable Disease8
Progressive Disease12
Unknown9
SecondaryDiscontinuations Due to Adverse Events

Adverse events were coded using the Medical Dictionary for Regulatory Activities, Version 11.0.

Time frame:
baseline, up to 18 weeks
Reported as:
Number · participants
Discontinuations Due to Adverse Events
participantsPemetrexed
Atrial fibrillation1
Febrile neutropenia (possibly related)1
Pneumonia (resulted in death)1
Respiratory failure (resulted in death)1
PrimaryOverview of Adverse Events

Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
baseline, up to 18 weeks
Reported as:
Number · participants
Overview of Adverse Events
participantsPemetrexed
TEAE - All, regardless of causality28
TEAE - Possibly related to study drug23
SAE - All, regardless of causality12
SAE - Possibly related to study drug1
Discontinuations Due to SAEs (including death)4
Discontinuations - Possibly related to study drug1
Discontinuations Due to Nonserious AEs0
Deaths - On Study2
Deaths - Possibly related to study drug0
Deaths - Within 30 days of Study Discontinuation0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed—12/31 (38.7%)28/31 (90.3%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPemetrexed
Atrial fibrillationCardiac disorders3/31
Abdominal painGastrointestinal disorders2/31
PyrexiaGeneral disorders2/31
PneumoniaInfections and infestations2/31
Respiratory failureRespiratory, thoracic and mediastinal disorders2/31
AnaemiaBlood and lymphatic system disorders1/31
Febrile neutropeniaBlood and lymphatic system disorders1/31
ThrombocytopeniaBlood and lymphatic system disorders1/31
Cardiac failureCardiac disorders1/31
Pericardial effusionCardiac disorders1/31
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPemetrexed
NauseaGastrointestinal disorders10/31
FatigueGeneral disorders9/31
AstheniaGeneral disorders8/31
ConstipationGastrointestinal disorders7/31
AnorexiaMetabolism and nutrition disorders7/31
AnaemiaBlood and lymphatic system disorders5/31
Oedema peripheralGeneral disorders5/31
DizzinessNervous system disorders5/31
CoughRespiratory, thoracic and mediastinal disorders5/31
DyspnoeaRespiratory, thoracic and mediastinal disorders5/31

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed
Median62.7 (35.7 to 77.5)
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed
Female4
Male27
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed
Caucasian30
Hispanic1
Region of Enrollment
Region of Enrollment(participants)Pemetrexed
Spain12
Denmark6
Germany13
Diagnosis
Diagnosis(participants)Pemetrexed
Non-Small Cell Lung Cancer (NSCLC)23
Mesothelioma8
Disease Stage
Disease Stage(participants)Pemetrexed
Stage III (locally advanced disease)12
Stage IV (metastatic disease)18
Unknown1
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed
0 - Fully Active14
1 - Ambulatory, Restricted Strenuous Activity17
Fluid Severity
Fluid Severity(participants)Pemetrexed
Mild15
Moderate14
Severe2

5 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kobenhavn, 2100, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hannover, 30625, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28041, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2006
First posted
Apr 20, 2006
Start
Dec 2006
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Jul 9, 2010
Last update
Jul 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00316225
First posted
Apr 20, 2006
Start date
Dec 2006
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Jul 9, 2010
Last update
Jul 9, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion